

## Carcinogenic Nitrogen Compounds. Part LXX.<sup>1</sup> Polycyclic Naphthyridines By Means of the Ullmann–Fetvadjian Reaction

By **N. P. Buu-Hoï** \* and **P. Jacquignon**, Institut de Chimie des Substances Naturelles du C.N.R.S., 91-Gif-sur-Yvette

**M. Mangane**, Institut Lannelongue de Recherches sur la Cancérogénèse Chimique et Hormonale, 92-Vanves, France

The Ullmann–Fetvadjian condensation of arylamines with  $\beta$ -naphthol and paraformaldehyde has been successfully applied to 5-amino-2-methoxypyridine and 3-aminoquinoline, cyclisation taking place at positions 6 and 4, respectively, to give 10-methoxynaphtho[2,1-*b*][1,5]naphthyridine and benzo[*f*]naphtho[2,1-*b*][1,7]naphthyridine; 4-hydroxycoumarin gave with 5-amino-2-methoxypyridine and with 4-amino-2-methylquinoline the corresponding benzopyranonaphthyridines.

NAPHTHO[2,1-*b*][1,5]NAPHTHYRIDINE (I) and its derivatives are hitherto unknown; in view of the possibility that such compounds, which are isosteric with both benz[*a*]anthracenes and the angular benzacridines, are carcinogenic,<sup>2</sup> a synthesis of this new heterocyclic system was sought. An extension of the Ullmann–Fetvadjian benzacridine synthesis<sup>3</sup> to 5-amino-2-methoxypyridine proved successful. The aminopyridine reacted with  $\beta$ -naphthol and paraformaldehyde to furnish a product homogeneous on g.l.c. and t.l.c., which showed a u.v. spectrum resembling that of benz[*a*]acridine. Proof that this compound was 10-methoxynaphtho[2,1-*b*][1,5]naphthyridine (II) (resulting from cyclisation at the

pyridine 6-position) and not the isomeric[1,7]naphthyridine (IV) (cyclisation at the pyridine 4-position) was obtained from the n.m.r. spectrum (Varian A60 spectrometer; solvent CCl<sub>4</sub>–CDCl<sub>3</sub>; internal reference Me<sub>4</sub>Si), which featured only one aromatic singlet (Table), corresponding to the *meso*-anthracenic proton; structure (IV) would require three aromatic singlets, corresponding to protons 8, 11, and 12. Although the reaction failed when  $\alpha$ -naphthol was used in place of  $\beta$ -naphthol, with 4-hydroxycoumarin and the aminopyridine a normal Ullmann–Fetvadjian condensation product was obtained, which we assigned the structure (V), 9-methoxy-[1]benzopyrano[4,3-*b*][1,5]naphthyridin-6-one, by


<sup>1</sup> Part LXIX, N. P. Buu-Hoï, P. Jacquignon, and M. Mangane, *J. Chem. Soc. (C)*, 1971, 1109.

<sup>2</sup> Cf. A. Lacassagne, N. P. Buu-Hoï, R. Daudel, and F. Zajdela, *Adv. Cancer Res.*, 1956, **4**, 315.

<sup>3</sup> Y

<sup>3</sup> F. Ullmann and A. Fetvadjian, *Ber.*, 1903, **36**, 1027; N. P. Buu-Hoï, *J. Chem. Soc.*, 1949, 670; 1950, 1146; 1951, 2871; *J. Chem. Soc., (C)* 1967 213.

analogy with structure (II).<sup>\*</sup> Both compounds (II) and (V) were readily demethylated by pyridine hydrochloride to give the corresponding hydroxy-compounds



(III) and (VI). An attempt to prepare the unsubstituted heterocycle (I; R = H) from 3-aminopyridine gave no well defined product.


Chemical shifts (p.p.m.) of compound (II)

Signal	Protons
4.12 (s)	Me
7.13 (d, $J_{8,9}$ 9 Hz) *	9
7.53—7.9 (complex)	2,3,4,5,6
8.21—8.36 (d, $J_{8,9}$ 9 Hz)	8
8.63—8.8 (m)	1
9.23 (s)	12

\* Strongly deshielded by MeO and by N in *meta*-position.

Whereas with 5-amino-2-methoxypyridine the Ullmann-Fetvadjan cyclisation takes place *ortho* to the ring nitrogen atom, with 3-aminoquinoline and  $\beta$ -naphthol it occurred at the *para*-position, to give benzo[*f*]naphtho[2,1-*b*][1,7]naphthyridine (VII),<sup>†</sup> which showed no band in the visible spectrum; had the reaction occurred at the *ortho*-position, the resulting isomeric compound (VIII) would absorb in the visible at least to the extent <sup>6</sup> of benzo[*a*]naphthacene and dibenz[*a,i*]acridine, which are both orange. This cyclisation at position 4 gave however only poor yields, and when 4-hydroxycoumarin was used in place of  $\beta$ -naphthol no trace of a naphthyridine derivative was obtained; the reverse trend was observed with 4-amino-2-methylquinoline, which gave no cyclised product with  $\beta$ -naphthol, whereas with 4-hydroxycoumarin, 8-methylbenzo[*h*][1]benzopyrano-

[4,3-*b*][1,6]naphthyridine-6-one (IX) was obtained in small yields.  $\alpha$ -Naphthol was less reactive than either  $\beta$ -naphthol or 4-hydroxycoumarin, as no naphthyridine derivative was formed either with 3-aminoquinoline or with 4-amino-2-methylquinoline. The difficulty in bringing about Ullmann-Fetvadjan condensations with



a pyridine ring to give naphthyridine derivatives is in sharp contrast with the ease with which such condensations occur with a benzene ring; thus, 5-amino-8-methylquinoline readily afforded 9-methyl[1]benzopyrano[4,3-*b*]pyrido[2,3-*h*]quinolin-6-one (X) with 4-hydroxycoumarin. This supports the notion that the Ullmann-Fetvadjan reaction involves an electrophilic substitution, which would occur more easily at sites of higher electron density.<sup>‡</sup>

Preliminary biological tests show the naphthyridine (VII) to have strong inducing activity in the biosynthesis of xoxazolamine hydroxylase in rats,<sup>§</sup> compound (II) to be only weakly active, and (III) to be completely inactive in this respect. Since carcinogenic compounds are generally excellent enzyme inducers in this test,<sup>9</sup> the naphthyridine (VII) is being assayed for carcinogenicity; results will be reported elsewhere.

## EXPERIMENTAL

10-Methoxynaphtho[2,1-*b*][1,5]naphthyridine (II).—To a boiling mixture of  $\beta$ -naphthol (1.5 g) and 5-amino-2-methoxypyridine (1.25 g), paraformaldehyde (0.45 g) was added in small portions, and once the vigorous reaction had subsided the product was fractionated *in vacuo*. The portion boiling at *ca.* 250° at 11 mmHg was treated

<sup>4</sup> Cf. C. A. Coulson and H. C. Longuet-Higgins, *Rev. scientifique*, 1947, **85**, 935.

<sup>5</sup> M. Colonna, *Boll. sci. fac. Chim. ind. Bologna*, 1948, **6**, 26.

<sup>6</sup> Cf. G. M. Badger, 'Six-Membered Heterocyclic Nitrogen Compounds with Three Condensed Rings,' ed. C. F. H. Allen, Interscience, New York, 1958, p. 551.

<sup>7</sup> See, for instance, R. Daudel, N. P. Buu-Hoï, and M. Martin, *Bull. soc. chim. France*, 1948, **15**, 1202.

<sup>8</sup> N. P. Buu-Hoï and D.-P. Hien, *Compt. rend.*, 1967, **D**, 264, 153.

<sup>9</sup> N. P. Buu-Hoï and D.-P. Hien, *Biochem. Pharmacol.*, 1969, **18**, 741.

\* The preferential cyclisation at the pyridine 2-position rather than the 4-position is also in line with the higher electron density at the former site.<sup>4</sup>

<sup>†</sup> Although the unsubstituted compound was not previously known, its 14-chloro-6-phenyl and 14-phenoxy-6-phenyl derivatives had been prepared by a different method.<sup>5</sup>

<sup>‡</sup> Nucleophilic substitution on quinolines takes place exclusively at positions 2 and 4 in the pyridine ring, *i.e.* at the positions of lowest  $\pi$ -electron density.<sup>7</sup>

<sup>§</sup> The corresponding dibenz[*a,j*]acridine is highly active in this test.<sup>8</sup>

with ethanol, and a brown insoluble residue was filtered off. The filtrate was concentrated, and the solid obtained on cooling was recrystallised from ethanol, giving the *naphthyridine* (II), as yellowish needles (1 g), m.p. 157°, showing deep yellow halochromism in sulphuric acid (Found: C, 78.2; H, 4.4; N, 10.7.  $C_{17}H_{12}N_2O$  requires C, 78.5; H, 4.6; N, 10.7%). The *picrate* formed yellow microprisms, m.p. 249° (decomp. >180°) (from toluene) (Found: N, 14.4.  $C_{23}H_{15}N_5O_8$  requires N, 14.3%). The purity of compound (II) was verified by t.l.c. (on silica) and g.l.c.

**10-Hydroxynaphtho[2,1-b][1,5]naphthyridine** (III).—A mixture of the methoxy-compound (II) (0.5 g) and freshly redistilled anhydrous pyridine hydrochloride (3 g) was heated under reflux for 5 min; the cooled product was treated with 1% aqueous acetic acid, and the precipitate was washed with water, dried, and purified by sublimation *in vacuo*. The *hydroxy-compound* (III) crystallised as pale yellow microneedles (0.3 g), m.p. 370° (from toluene) (Found: C, 78.1; H, 4.9; N, 11.3.  $C_{16}H_{10}N_2O$  requires C, 78.1; H, 4.9; N, 11.4%). It gave a greenish yellow halochromism in sulphuric acid, but did not form a *picrate*.

**9-Methoxy[1]benzopyrano[4,3-b][1,5]naphthyridin-6-one** (V).—To a mixture of 4-hydroxycoumarin (3.15 g) and 5-amino-2-methoxypyridine (2.5 g) heated at *ca.* 220°, paraformaldehyde (0.9 g) was added in small portions, and the product was distilled *in vacuo*. The reddish resin obtained, b.p. >300°/11 mm, was triturated with ethanol, and the solid product was recrystallised twice from ethanol–benzene (1 : 1), to give the *naphthyridine* (V) as pale yellow needles (1 g), m.p. 231°, showing yellow halochromism in sulphuric acid, and giving no *picrate* (Found: C, 68.4; H, 3.8; N, 9.8.  $C_{16}H_{10}N_2O_3$  requires C, 68.6; H, 4.0; N, 10.0%). **9-Hydroxy[1]benzopyrano[4,3-b][1,5]naphthyridin-6-one**, (VI), prepared in almost quantitative yield from the foregoing methoxy-compound with pyridine hydrochloride, was purified by sublimation *in vacuo*, and formed pale yellow needles, m.p. >370° (Found: C, 68.2; H, 3.8; N, 10.5.  $C_{15}H_8N_2O_3$  requires C, 68.2; H, 3.8; N, 10.6%).

**Benzo[f]naphtho[2,1-b][1,7]naphthyridine** (VII).—An

Ullmann-Fetvadjian reaction with 3-aminoquinoline (3 g),  $\beta$ -naphthol (3 g), and paraformaldehyde (0.9 g) afforded a product which, on distillation *in vacuo*, gave a yellow resin, b.p. >300° at 0.1 mmHg. This solidified on trituration with butanol; the solid was recrystallised from benzene–butanol (1 : 1) to give the *naphthyridine* (VII)<sup>10</sup> as pale yellow needles (0.9 g), m.p. 215°, showing orange halochromism in sulphuric acid (Found: C, 85.5; H, 4.5; N, 9.7.  $C_{26}H_{12}N_2$  requires C, 85.7; H, 4.3; N, 10.0%),  $\nu_{\max}$  (EtOH) 228 ( $\epsilon$  24,700), 296 (29,411), 360 (5882), 380 (6470), and 400 nm (7058); *picrate*, yellow prisms, m.p. 245° (decomp. >210°) (from toluene) (Found: N, 13.5.  $C_{26}H_{15}N_5O_7$  requires N, 13.8%).

**8-Methylbenzo[h][1]benzopyrano[4,3-b][1,6]naphthyridin-6-one** (IX).—The Ullmann-Fetvadjian reaction with 4-amino-2-methylquinoline (3 g), 4-hydroxycoumarin (3.2 g), and paraformaldehyde (0.45 g) furnished, on distillation of the product *in vacuo*, a portion boiling at *ca.* 320° at 0.5 mmHg, which gave the *naphthyridine* (IX) as yellow, sublimable needles (1 g), m.p. 306° (from butanol), showing greenish-yellow halochromism in sulphuric acid (Found: C, 76.7; H, 3.9; N, 8.7.  $C_{20}H_{12}N_2O_2$  requires C, 76.9; H, 3.9; N, 9.0%). This compound did not give a *picrate*.

**9-Methyl[1]benzopyrano[4,3-b]pyrido[2,3-h]quinolin-6-one** (X).—Similarly prepared from 5-amino-8-methylquinoline (1.5 g), 4-hydroxycoumarin (1.6 g), and paraformaldehyde (0.4 g), this *quinoline*, b.p. >360° at 11 mmHg, crystallised from butanol–xylene (1 : 1) as pale yellow needles (0.7 g), m.p. 327°, giving a yellow halochromism in sulphuric acid (Found: C, 76.6; H, 4.2; N, 9.3%).

This work was supported by l'Institut National de la Santé et de la Recherche Médicale (Director, Prof. C. Burg) and the S.E.I.T.A. (Research Director, Dr. P. Vespérini).

[0/1471 Received, August 26th, 1970]

<sup>10</sup> For orientation in the Skraup cyclisation of 3-aminoquinoline, see N. P. Buu-Hoï, R. Royer, and M. Hubert-Habart, *J. Chem. Soc.*, 1956, 2048.